This study is interesting, because among other things, it shows that if TSH has been low for some time, even after 10 years "correction, it does not rise for about half the subjects. And T4 therapy was started in quite a large minority of patients with TSH < 5 mIU/L. I don't like the definitions of under and over treatment as regards TSH values for most, but the risks seem very small. Behind a paywall
Risk of over-and under-treatment with levothyroxine in primary care in Copenhagen, Denmark
J L la Cour, BR Medici, Mia Klinten Grand ,DR Nicolaisdottir, B Lind et al
European Journal of Endocrinology 185:673-679: 2021
Doi: doi.org/10.1530/EJE-21-0485
Objective
A decrease over time in thyroid stimulating hormone (TSH) levels when initiating levothyroxine (L-T4) therapy for hypothyroidism has been reported, where treatment most often is initiated with TSH levels below 10 mIU/L. The primary objective of this study was to investigate whether this lower TSH threshold resulted in an increased number of overtreated patients.
Design and method
Retrospective cohort study comprising inhabitants in Copenhagen had TSH measurements requested by general practitioners which led to a new prescription of L-T4 between 2001 and 2012. Over- and under- treatment were defined as TSH <0.1 mIU/L or above 10 mIU/mL, respectively, in three consecutive measurements. Data were analyzed by Aalen–Johansen estimators and Cox proportional hazards models.
Results
In total, 14 533 initiations of L-T4 were included in the study. The cumulative risk of being over- or undertreated was 4.7 and 7.4% after 10 years. The hazard of overtreatment was higher among women, younger adults, and with lower initial TSH levels. The hazard of overtreatment decreased over the time period from 2001 to 2012. Among overtreated individuals, the chance of returning to a normal TSH was about 55% after 10 years. In 18% of the cases, L-T4 therapy was initiated on TSH levels less than 5 mIU/L.
Conclusion
Although a still decreasing threshold for initiating L-T4 therapy is known, the risk of overtreatment (and undertreatment) was low and lessened in the period 2001–2012 among Danish primary